Healthcare | September 24, 2022
Madhavbaug plans to foray in UAE, Europe & US
To set up 50 lifestyle modification centres across the UAE in the next 24 months
To set up 50 lifestyle modification centres across the UAE in the next 24 months
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
The #pledgemyeyes initiative reached out to over 30 million people across the country and the website registered 3X more pledges compared to the present numbers
The plant is a dedicated for manufacturing of Mouth dissolving strip.
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
Subscribe To Our Newsletter & Stay Updated
